1. Home
  2. THRD vs LXEO Comparison

THRD vs LXEO Comparison

Compare THRD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • LXEO
  • Stock Information
  • Founded
  • THRD 2019
  • LXEO 2017
  • Country
  • THRD United States
  • LXEO United States
  • Employees
  • THRD N/A
  • LXEO N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • LXEO
  • Sector
  • THRD Health Care
  • LXEO
  • Exchange
  • THRD Nasdaq
  • LXEO Nasdaq
  • Market Cap
  • THRD 157.7M
  • LXEO 140.6M
  • IPO Year
  • THRD 2022
  • LXEO 2023
  • Fundamental
  • Price
  • THRD $3.55
  • LXEO $2.95
  • Analyst Decision
  • THRD Hold
  • LXEO Strong Buy
  • Analyst Count
  • THRD 3
  • LXEO 5
  • Target Price
  • THRD $5.00
  • LXEO $22.80
  • AVG Volume (30 Days)
  • THRD 343.0K
  • LXEO 819.0K
  • Earning Date
  • THRD 05-14-2025
  • LXEO 05-08-2025
  • Dividend Yield
  • THRD N/A
  • LXEO N/A
  • EPS Growth
  • THRD N/A
  • LXEO N/A
  • EPS
  • THRD N/A
  • LXEO N/A
  • Revenue
  • THRD N/A
  • LXEO N/A
  • Revenue This Year
  • THRD N/A
  • LXEO N/A
  • Revenue Next Year
  • THRD N/A
  • LXEO N/A
  • P/E Ratio
  • THRD N/A
  • LXEO N/A
  • Revenue Growth
  • THRD N/A
  • LXEO N/A
  • 52 Week Low
  • THRD $3.18
  • LXEO $2.32
  • 52 Week High
  • THRD $16.94
  • LXEO $19.50
  • Technical
  • Relative Strength Index (RSI)
  • THRD 42.90
  • LXEO 41.97
  • Support Level
  • THRD $3.34
  • LXEO $2.90
  • Resistance Level
  • THRD $3.68
  • LXEO $4.59
  • Average True Range (ATR)
  • THRD 0.14
  • LXEO 0.52
  • MACD
  • THRD 0.07
  • LXEO 0.06
  • Stochastic Oscillator
  • THRD 62.86
  • LXEO 22.41

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

Share on Social Networks: